These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Current advances in retroviral gene therapy. Yi Y; Noh MJ; Lee KH Curr Gene Ther; 2011 Jun; 11(3):218-28. PubMed ID: 21453283 [TBL] [Abstract][Full Text] [Related]
26. Integration of retroviral vectors. Gabriel R; Schmidt M; von Kalle C Curr Opin Immunol; 2012 Oct; 24(5):592-7. PubMed ID: 22981243 [TBL] [Abstract][Full Text] [Related]
27. Integration site selection by retroviral vectors: molecular mechanism and clinical consequences. Daniel R; Smith JA Hum Gene Ther; 2008 Jun; 19(6):557-68. PubMed ID: 18533894 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of retroviral integration and mutagenesis. Cavazza A; Moiani A; Mavilio F Hum Gene Ther; 2013 Feb; 24(2):119-31. PubMed ID: 23330935 [TBL] [Abstract][Full Text] [Related]
30. Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Bosticardo M; Ghosh A; Du Y; Jenkins NA; Copeland NG; Candotti F Mol Ther; 2009 Nov; 17(11):1910-8. PubMed ID: 19638958 [TBL] [Abstract][Full Text] [Related]
31. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Scobie L; Hector RD; Grant L; Bell M; Nielsen AA; Meikle S; Philbey A; Thrasher AJ; Cameron ER; Blyth K; Neil JC Mol Ther; 2009 Jun; 17(6):1031-8. PubMed ID: 19337236 [TBL] [Abstract][Full Text] [Related]
32. Retroviral vector production. Miller AD Curr Protoc Hum Genet; 2014 Jan; 80():12.5.1-12.5.22. PubMed ID: 24510681 [TBL] [Abstract][Full Text] [Related]
33. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand? Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362 [TBL] [Abstract][Full Text] [Related]
34. Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice. Montini E; Cesana D Methods Enzymol; 2012; 507():171-85. PubMed ID: 22365774 [TBL] [Abstract][Full Text] [Related]
35. Curing genetic disease with gene therapy. Williams DA Trans Am Clin Climatol Assoc; 2014; 125():122-8; discussion 128-9. PubMed ID: 25125725 [TBL] [Abstract][Full Text] [Related]
36. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499 [TBL] [Abstract][Full Text] [Related]
37. Retroviral vectors for analysis of viral mutagenesis and recombination. Rawson JM; Mansky LM Viruses; 2014 Sep; 6(9):3612-42. PubMed ID: 25254386 [TBL] [Abstract][Full Text] [Related]
38. The history and principles of retroviral vectors. Dornburg R Front Biosci; 2003 May; 8():d818-35. PubMed ID: 12700110 [TBL] [Abstract][Full Text] [Related]
39. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. Haviernik P; Bunting KD Curr Gene Ther; 2004 Sep; 4(3):263-76. PubMed ID: 15384940 [TBL] [Abstract][Full Text] [Related]
40. Insertional gene activation by lentiviral and gammaretroviral vectors. Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]